Genscript Biotech (HK:1548) has released an update. Genscript Biotech’s subsidiary, Probio Nanjing, has entered into a significant ...
Investor's Business Daily on MSN6h
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsMerck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...
Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday said it has secured an ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback